SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018612
Filing Date
2023-11-09
Accepted
2023-11-09 16:46:52
Documents
59
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20230930x10q.htm   iXBRL 10-Q 2234134
2 EX-31.1 tbph-20230930xex31d1.htm EX-31.1 13468
3 EX-31.2 tbph-20230930xex31d2.htm EX-31.2 14245
4 EX-32 tbph-20230930xex32.htm EX-32 16268
  Complete submission text file 0001558370-23-018612.txt   7407469

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20230930.xsd EX-101.SCH 43299
6 EX-101.CAL tbph-20230930_cal.xml EX-101.CAL 57331
7 EX-101.DEF tbph-20230930_def.xml EX-101.DEF 202331
8 EX-101.LAB tbph-20230930_lab.xml EX-101.LAB 387656
9 EX-101.PRE tbph-20230930_pre.xml EX-101.PRE 286176
53 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20230930x10q_htm.xml XML 1195139
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 231393392
SIC: 2834 Pharmaceutical Preparations